Clinical Trial

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
Protocol Amendment History 1 change
notable Trial sites expanded: 30 -> 38 locations 2026-04-18
Trial Details
NCT Number NCT07217067
Lead Sponsor Novartis Pharmaceuticals
Conditions Atrial Fibrillation
Enrollment 165 participants
Start Date 2025-10-28
Primary Completion 2027-09-09 (estimated)
Study Completion 2027-09-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-31